MARLBOROUGH, Mass.--(BUSINESS WIRE)--Feb. 10, 2005--EXACT Sciences Corporation (NASDAQ: EXAS) announced today that the American Journal of Preventive Medicine has published the results of a patient preference study, which found that patients perceived stool-based DNA testing to have many advantages over both fecal occult blood testing (FOBT) and colonoscopy, and preferred stool-based DNA testing for their routine colorectal cancer screening.
